Edwards Lifesciences Corporation Stock News

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 126.67% and 18.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Edwards Lifesciences (NYSE:EW) moved higher by 3.5% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 75.36% year over year to $0.3

Late Thursday, Edwards Lifesciences reported adjusted income of 34 cents per share on $925 million in sales for its second quarter ended June 30. In response, EW stock popped.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarte

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) Bio-Rad Laboratories,...

Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Large-Cap Growth Fund posted a return of 27.86% for the quarter, outperforming its benchmark, t

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Abbott posted a good second quarter, with the expected outperformance in diagnostics, but also better results in devices, diabetes, and nutrition.

Most readers would already be aware that Edwards Lifesciences' (NYSE:EW) stock increased significantly by 9.3% over...

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Paul A. LaViolette has bee

Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces in

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) * Altimmune Inc (NASDAQ: ALT) (announced positive pre

The two companies' agreement puts to rest an escalating dispute over heart valve repair products.